What is systemic sclerosis?
Systemic sclerosis (systemic scleroderma) is a multisystem disease that results in fibrosis and vascular abnormalities in association with autoimmune changes. These lead to breakdown of the skin, subcutaneous tissue, muscles and internal organs (e.g. digestive tract, heart, lungs and kidneys). The skin becomes thickened and tightly bound to underlying structures.
Localised scleroderma (also known as morphoea) is an unrelated skin disease and is confined to the skin.
Who gets systemic sclerosis?
Systemic sclerosis is a rare condition that may occur in people of any race, although it is less common in people of Asian descent. It appears to be three to four times more common in women than men and is comparatively rare in children. It usually starts between 30-40 years in women and later in men.
What causes systemic sclerosis?
Systemic sclerosis is classified as an autoimmune disease of an unknown cause. This means the immune system is reacting against one's own tissues. Pathogenesis involves both activated B cells and activated T lymphocytes. Autoantibodies and cytokines injure the cells that line blood vessels (endothelial cells) causing vasoconstriction, and fibroblasts, resulting in excessive production of collagen (fibrosis).
Certain factors have been identified that may trigger the disease. These include injury, drugs (e.g. vitamin K, cocaine, penicillamine, appetite suppressants and some chemotherapeutic agents), and chemicals (e.g. silica, organic solvents, pesticides, aliphatic hydrocarbons and epoxy resin).
What are the clinical features of systemic sclerosis?
Raynaud phenomenon is usually the first symptom of systemic sclerosis. Patients experience episodes of vasospasm , which causes blood vessels in the fingers and toes to constrict. As less blood is reaching these extremities the skin changes colour to white and the fingers and toes may feel cold and numb. As they warm up, they go blue and then red before returning to normal again.
Cutaneous features of systemic sclerosis
Other skin changes include:
- Itchy skin
- Thickening of the skin of the fingers, then atrophy (thinned) and sclerosis (scarring). The fingers become spindle-shaped (sclerodactyly) from resorption of the fingertips.
- Fragile nails become smaller with ragged cuticles
- Taut, shiny skin that may affect most parts of the body, including the face, resulting in loss of expression and difficulty opening the mouth properly.
- Dark or pale patches (hyperpigmentation or hypopigmentation). These are often described as having a "salt and pepper" appearance.
- Visibly dilated blood vessels (telangiectases) appear on the fingers, palms, face, lips, tongue and chest.
- Calcinosis (calcium deposits) develops in the skin, particularly the fingers, hands and other bony areas. These can breakdown and discharge chalky material.
- Ulcers may follow minor injuries over the joints, or on the tips of fingers and toes where the circulation is poor. Ulceration can lead to dry gangrene and eventual loss of the tips of the fingers (like frost bite).
- Ulcers may also arise over calcinosis and on the lower legs.
- Sicca symptoms (dry eyes, dry mouth) and Sjogren syndrome
Ulcerated and resorbing fingertips
Ulcerated and resorbing fingertips
Systemic sclerosis affecting other organs
In addition to the skin changes, the disease affects many other organs. Problems that may occur include:
- Friction rubs over the joints and tendons, particularly the knees.
- Eye changes with tightness of lids, reduced tear secretion, retinopathy
- Joint pain, muscle pain and weakness and limited movement resulting in contractures.
- The digestive tract may be affected throughout its length. Oesophageal reflux is common causing difficulty in swallowing solid and liquid food. This can lead to nausea, vomiting, weight loss, stomach cramps, diarrhoea, constipation and bleeding.
- Lung and heart involvement may manifest as shortness of breath, high blood pressure, chest pain, pleurisy, pneumothorax, pericarditis arrhythmias, general heart enlargement and heart failure.
- Progressive kidney disease resulting in proteinuria, high blood pressure and eventually renal failure.
What is the CREST syndrome?
CREST syndrome (also called CRST syndrome) is a limited form of systemic sclerosis in which there is Calcinosis, Raynaud's phenomenon, oEsophageal involvement, Sclerodactyly and Telangiectases. Characteristically, the telangiectases are well-defined and flat (matt).
How is systemic sclerosis diagnosed?
The diagnosis of systemic sclerosis is generally made from the patient's history and the findings on examination of the skin and other organs. Nailfold capillaroscopy typically shows loss of capillaries, haemorrhages and disorganised, enlarged capillaries. A skin biopsy is not usually necessary but characteristically shows excessive ground substance and odd-looking endothelial cells in the dermis, and later, deposits of collagen. The epidermis is usually atrophic (thinned).
Up to 90% of patients with systemic sclerosis have elevated antinuclear antibodies (ANA) but these are less frequent than in the more common connective tissue disease, systemic lupus erythematosus. Thyroid antibodies may occur and result in an under-active thyroid gland
Anticentromere antibodies are characteristic of CREST syndrome and may be present in patients with Raynaud phenomenon before systemic sclerosis appears. Scl-70 is unique to systemic sclerosis and is more likely to be associated with severe systemic sclerosis involving the lungs. Many other less specific antibodies have been reported to be associated with different patterns of disease.
Anaemia, raised sedimentation rate (ESR) and increased gamma globulins (hypergammaglobulinaemia) and varying immune abnormalities are quite common especially positive rheumatoid factors. Blood clotting tests are done in case of coagulopathy associated with lupus anticoagulant and anticardiolipin.
What is the treatment of systemic sclerosis?
There is no cure for systemic sclerosis and treatment is aimed at controlling symptoms and preventing complications. Because the symptoms of systemic sclerosis are so diverse a team of medical specialists is usually necessary.
It is absolutely essential to discontinue smoking. Avoid vasoconstrictive drugs, such as decongestants, amphetamines, ergotamine. Hypertension should be controlled.
The mainstay of treatment is with immune modulating agents, including:
- Oral corticosteroids
- Biologics including TNFα inhibitors and rituximab
- Autologous haemopoietic stem cell transplantation
Targeted therapy is being developed against specific cytokines and peptide mediators involved in systemic sclerosis.
|Joint and muscle||
- Textbook of Dermatology. Ed Rook A, Wilkinson DS, Ebling FJB, Champion RH, Burton JL. Fourth edition. Blackwell Scientific Publications.
- Vitiello M, Abuchar A, Santana N, Dehesa L, Kerdel FA. An Update on the Treatment of the Cutaneous Manifestations of Systemic Sclerosis: The Dermatologist's Point of View. J Clin Aesthet Dermatol. 2012 Jul;5(7):33-43.
- Nitsche A. Raynaud, digital ulcers and calcinosis in scleroderma. Reumatol Clin. 2012 Sep-Oct;8(5):270-7. Epub 2012 Jul 25. Review. PubMed PMID: 22835924.
On DermNet NZ:
- Mixed connective tissue disease
- Systemic diseases
- Connective tissue diseases
- Localised scleroderma (morphoea)
- Scleroderma – Medline Plus
- Scleroderma Foundation
- Scleroderma Australia
- Scleroderma Research Foundation
- Arthritis Foundation of New Zealand – Scleroderma Support Group
- Systemic sclerosis – Medscape Reference
- Patient information: Scleroderma (The Basics) – UpToDate (for subscribers)
- FESCA: Federation of European Scleroderma Assocations
- Raynauds and Scleroderma Ireland
Books about skin diseases:
See the DermNet NZ bookstore